Uterine Sarcomas: A Retrospective Analysis of a Cohort of 62 Patients

Abstract

Background and objective Uterine sarcomas are rare tumors, and they account for 4% of all uterine malignancies. These tumors are characterized by a great diversity of histological types, and current knowledge regarding their treatment is limited. The aim of our study was to analyze a cohort of patients with uterine sarcomas with respect to the histological types of their tumors, as well as their prognosis and treatment. Materials and methods This was a retrospective analysis involving patients diagnosed at a single center with uterine sarcoma between 2003 and 2017. Results The study included 62 patients; the mean age of the patients was 62 ±13 years. Carcinosarcoma was identified in 44% of cases, leiomyosarcoma in 40%, and endometrial stromal sarcoma in 13%. Endometrial stromal sarcoma was found to occur in younger women compared to carcinosarcoma (52 ±13 vs. 66 ±12 years, p=0.016); 90% of patients underwent surgery, and medical treatment was implemented in 42%. The mean overall survival (OS) was 93 ±10.65 months, and the median progression-free survival (PFS) was 12 months. There was a significant association between the stage of the disease at diagnosis and the probability of survival: mean OS was 118 months for locoregional disease vs. 44 months for metastatic disease (p<0.001). The overall five-year survival rate was 39%. Discussion and conclusions Uterine sarcomas are rare cancers, and they are very heterogeneous. They are also associated with a high mortality rate. Further investigational studies are required so that a more effective treatment method and individualized treatment plans can be implemented for patients with uterine sarcoma.

Retrospective Analysis of Patients with Gynaecological Uterine Sarcomas in a Tertiary Hospital

“…In our study, CSs represented 45.3% of cases, followed by LMSs, which constituted 31.7%. Taking into account other published studies that included CSs, despite the change in FIGO staging, the results herein are similar to those of Eiriz et al, 44% [11], and other studies [12], lower than that reported by Sait et al, 58% [9], and higher than that reported by Gao Y. et al, 23% [3]. We do not know the substantial basis for these differences, but they may be due to differences in the mean age of the patients treated by each centre.…”

“…Again, taking into account the entire series and focusing on clinical variables, particularly age, herein, the mean age at diagnosis was 59.5 years, very similar to other studies [4,5,[8][9][10][11]. Among the subgroups, there were significant differences, highlighting 4 years earlier in the ESS group and 3 years later in the CS and other sarcoma groups (p < 0.001).…”

“…The initial selection identified a total of 7330 that did not meet the inclusion criteria after applying filters. Of a total of 195 studies that were retrieved to evaluate eligibility, 18 were selected as relevant [1,[3][4][5][6][8][9][10][11][12][13][15][16][17][18][19][20][21]. Figure 3 shows a flow chart that illustrates the selection of studies.…”

“…These tumours tend to metastasize and recur early; therefore, the prognosis is poor, with an overall 5-year survival rate lower than 50% [4,[11][12][13][14].…”

Identification of Ferroptosis-Related Gene Prognostic Signature and HSF1 for Reversing Doxorubicin and Gemcitabine Resistance in Uterine Carcinosarcoma

“…As most patients are asymptomatic at the time of diagnosis, therefore, they usually have poor prognosis. The heterogeneous of UCS is the critical factor for the different treatment response and prognosis [ 4 ]. However, there is an urgent need to explore molecular mechanisms and identify of novel biomarkers in the treatment and prognosis of UCS.…”